view Commencement of Circadian non-executive director share plan view Circadian and CSIRO enter strategic research alliance view Results of Annual General Meeting view 2009 AGM Managing Director's Presentation view CIR to present at Merriman Curhan Ford`s US Investor Summit view Circadian subsidiary terminates licence to Ark Therapeutics view Open Briefing - CEO on Manufacturing Milestone and Update view 2009 Annual Report view Notice of Annual General Meeting view Manuafacturing milestone achieved for cancer drug candidate VGX-300 view Change of date for Circadian's 2009 AGM view Change of Director's Interest Notice - Robert Klupacs view Change in substantial holder view Circadian provides PerkinElmer with worldwide rights to market research products view Circadian Newsletter - September 2009 view Circadian granted key VEGF-C patent in Japan view Initial Director's Interest Notice - Dr Errol Malta view Dr Errol Malta appointed non-executive director view Preliminary final report view Shares to be released from escrow view Corporate Presentation view Appendix 3B - Employee incentive view Circadian granted key strategic VEGF-D patent in Europe for angiogenic applications view Circadian sponsors international conference on angiogenesis research view Circadian licensee Ark Therapeutics announces Trinam® phase III study enrols first patient view Open Briefing - CEO on Recent Achievements view FINSIA presentation - "The Survivors: strong business and balance sheet" view Circadian Scientific Advisory Board Chairman, Prof. Kari Alitalo, wins prestigious award for biomedical research view BioMelbourne Network presentation - Transformation of Circadian view Change of Director's Interest Notice - Dominique Fisher view Circadian partner ImClone Systems demonstrates VEGFR-3 antibody improves anti-tumour effects of chemotherapy in mouse tumour models view Circadian Newsletter - April 2009 view Corporate Presentation view Open Briefing on Cancer Diagnostic Commercialisation view Circadian and Healthscope to commercialise Peter Mac Cancer Diagnostic view Half-Year Results & Operational Achievements view Open Briefing - CEO on Trinam Phase III Trial view Ark Therapeutics receives clearance to commence Phase 3 trial of Trinam
